| Literature DB >> 25860350 |
Zhenlei Liu1, Xixi Tao2, Yuexin Chen3, Zhongjie Fan4, Yongjun Li3.
Abstract
INTRODUCTION: Bed rest has been considered as the cornerstone of management of deep vein thrombosis (DVT) for a long time, though it is not evidence-base, and there is growing evidence favoring early ambulation.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25860350 PMCID: PMC4393252 DOI: 10.1371/journal.pone.0121388
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow diagram of study selection.
Main characteristics of 13 studies included in the meta-analysis.
| Study/author year | Country of study | Study design | Patients Male no./Female no. / Mean Age ± SD (years) | Intervention | Primary endpoints | Outcome(end events/total patients) |
| ||
|---|---|---|---|---|---|---|---|---|---|
| Anticoagulation regimen | Bed rest duration /ambulation date | bed rest | ambulation | ||||||
| Schellong 1999 [ | German | RCT | No details | LMWH+Warfarin | 8 days /day 0 | PE assessed by serial ventilation /perfusion SPECT in 8~10 day | 10/59 | 14/63 | 0.25 |
| Ashwanden 2001 [ | Switzerland | RCT | 72/57/65±17 | LMWH+VitK antagonist | 4 days /day 0 | PE detected by scintigraphy in 3 months | 6/60 | 10/69 | 0.44 |
| Blattler 2003 [ | Austria | RCT | No details | LMWH+VitK antagonist | 9 days /day 0 | Progression of DVT | 4/10 | 6/27 | <0.01 |
| Trujillo-Santos 2005 [ | Spain | Prospective study | 1118/920/No details | LMWH | ≥3 days /No details | Symptomatic PE in 15 days | 7/1050 | 4/988 | NS |
| Junger 2006 [ | German | RCT | 57/45/60.4±14.5 | Dalteparin + ph enprocoumon | ≥5 days /day 0 | Combined | 14/50 | 7/53 | 0.088 |
| Romera 2006 [ | Spain | RCT | 78/68/60.7 | LMWH+Warfarin | 5 days /day 0 | Symptomatic PE during first 10 days | 2/67 | 2/79 | 0.33 |
| Isma 2007 [ | Sweden | RCT | 39/33/54±14 | LMWH+Warfarin | No details /immediately | recanalization of occluded vein within 6 months | - | - | NS |
| Romera 2008 [ | Spain | RCT | 118/101/64.2 | LMWH+Warfarin | 5 days /day 0 | Symptomatic PE during first 10 days | 2/105 | 3/114 | 0.54 |
| Manganaro 2008 [ | Italy | Retrospective case-control study | 118/134/65±17 | LMWH+oral anticoagulation | 7±2 days or permanently /day 0 | Combined | 43/80 | 18/172 | <0.001 |
| Rahman 2009 [ | Turkey | RCT | 17/7/52.08 | Unfractionated heparin/LMWH+Warfarin | 7 days /day 0 | Improvement of venous outflow at day 7 | - | - | NS |
| Huang 2010 [ | China | RCT | 21/19/61 | LMWH+Warfarin | 7~10 days /d 1~2 | Symptomatic PE during 3 months | 0/20 | 0/20 | NS |
| Feng 2011 [ | China | nRCT | 11/21/60.5 | LMWH+Warfarin | 7 days /day 0 | PE(symptomatic or detectable by CT) in 7 days | 1/17 | 1/15 | >0.05 |
| Liu 2013 [ | China | RCT | 38/22/57.0 | Routine anticoagulation | 7~14 days /day 1~2 | symptomatic PE during 3 months | 0/30 | 0/30 | NS |
a Favors ambulation.
b Partial data eligible for the meta-analysis was extracted. For this reason the details about mean age of these patients were not available.
c Combined endpoints: progression of DVT documented by duplex sonography or phlebography, new PE detected by scintigraphy or CT.
d No detail was mentioned in the article.
e Considering the grouping design, we only included partial data of the study (Group A and Group C).
NS not significant; RCT randomized controlled study; nRCT non-randomized controlled study; ECG electrocardiogram.
Fig 2Summary of risk of bias for RCTs (RevMan 5.3).
Red: High risk; Yellow: Unclear risk; Green: Low risk * Because the studies compared bed rest versus ambulation, it is too easy for the patients to find out which group they are in. So it is not likely to fulfill the requirement of blinding of participants. ** Details about the reasons for this assessment are listed in the supporting information S3 Table.
Quality assessment of cohort studies based on the Newcastle-Ottawa Scale (range, 1–9 stars).
| Study | Selection | Comparability | Outcome | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Representativeness of exposed cohort | Selection of non-exposed cohort | Ascertainment of exposure | Demonstration that outcome was not at the start | Control for main factor | Controls for additional factor | Assessment | Follow-up was long enough | Adequacy of follow-up | ||
| Trujillo-Santos 2005 [ | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 6 |
| Manganaro 2008 [ | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 5 |
| Feng 2011 [ | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 5 |
Fig 3Funnel plot of studies included.
Fig 4Begg’s and Egger’s tests for publication bias of included studies.
Fig 5Meta-analysis of the incidence of primary end events among 1674 DVT patients with early ambulation and 1595 DVT patients with bed rest.
Summary of subgroup and sensitivity analyses of primary endpoints.
| Number of studies | Heterogeneity | RD (95% CI) | Effect size |
| |||
|---|---|---|---|---|---|---|---|
| Chi2(for FE | I2 |
| |||||
| Total studies (FE) | 13 | 148.16 | 92% | <0.00001 | −0.003 (−0.005, −0.002) | 4.79 | <0.00001 |
| Total studies (RE) | 13 | 0.01 | - | - | −0.03 (−0.05, −0.02) | 1.24 | 0.22 |
| Omitting Manganaro’s study [ | 12 | 6.30 | 0% | 0.85 | −0.00 (−0.02, 0.01) | 0.69 | 0.49 |
| Omitting Trujillo’s study [ | 12 | 94.76 | 88% | <0.00001 | −0.09 (−0.12, −0.05) | 4.77 | <0.00001 |
| Omitting Trujillo’s study [ | 12 | 0.01 | - | - | −0.094 (−0.12, 0.03) | 1.18 | 0.24 |
| Subgroup analysis | |||||||
| RCTs (FE) | 10 | 6.42 | 0% | 0.70 | −0.01 (−0.04, 0.03) | 0.44 | 0.66 |
| nRCTs (FE) | 3 | 203.30 | 99% | <0.00001 | −0.04 (−0.06, −0.03) | 6.64 | <0.00001 |
| nRCTs (RE) | 3 | 0.25 | - | - | −0.14 (−0.71, 0.42) | 0.49 | 0.62 |
*FE fixed effect model
**RE random effect model.
***In a random effect model, Tau2 should be employed to indicate the heterogeneity rather than I2 and p value.
Fig 6Meta-analysis of VAS change.
In this figure, the data in “Mean” and “SD” column is the mean change of VAS rather than initial mean VAS.
Fig 7Subgroup analysis of VAS change during the treatment period.
Fig 8Meta-analysis of change of circumference of affected limb.